Currently Viewing:
Evidence-Based Diabetes Management April 2015
When Moving to Collaborative Care, a Challenge Is Figuring Out How to Pay for It
Mary K. Caffrey
Currently Reading
Studies Are Showing SGLT2s Also Help Control Hypertension, Eliminate Some Side Effects
Andrew Smith
What NCQA Recognition Means for Patients With Diabetes
Robert A. Gabbay, MD, PhD, FACP
A Look at the Unhealthiness of Sitting, and a Call for More Research on Its Effects
Mary K. Caffrey
TV Watching Appears Worse Than Other Forms of Sitting
Mary K. Caffrey
Study Finds Older Adults With T2DM, Comorbidities Aren't Getting Enough Treatment Time
Tony Hagen
Implementing JNC 8 Guidelines Is Generally Cost-Effective, According to NEJM Findings
Mary K. Caffrey
Weighing the Options With Bariatric Surgery: Long-Term Results Compare Risks, Health Outcomes
Surabhi Dangi-Garimella, PhD
Dietary Panel Releases Report, Cholesterol Removed From List of Nutrients to Avoid
Mary K. Caffrey
Higher-Dose Liraglutide Creates New Options to Fight Obesity, but Payment Remains a Challenge
Andrew Smith
Obesity Among Children and Teens Demands Stronger Response, Lancet Authors Find
Mary K. Caffrey
FDA Approves Toujeo, Basal Insulin Seen as Successor to Lantus
Mary K. Caffrey
Glyxambi Approved, Combo Provides Actions of SGLT2, DPP-4 Inhibitors for Patients With T2DM
Mary K. Caffrey
FDA Approves Aflibercept for Diabetic Retinopathy in Patients With Diabetic Macular Edema
Mary K. Caffrey
Panel Discusses ACA's Effect on Mental Health Delivery, Care for Those With Comorbidities
Mary K. Caffrey
AMA, CDC Launch Prevent Diabetes STAT to Prevent More Cases of Type 2
Mary K. Caffrey

Studies Are Showing SGLT2s Also Help Control Hypertension, Eliminate Some Side Effects

Andrew Smith
Real-world studies of SGLT2 inhibitors show that this new class of drugs for type 2 diabetes has lowered A1C more than rivals. Patients lose more weight than with other oral therapies, and the benefit of controlling hypertension may make it possible for some patients to stop taking other drugs.
 
• an enhanced pharmacovigilance program that monitors malignancies, serious cases of pancreatitis, severe hypersensitivity reactions, photosensitivity reactions, liver abnormalities, and adverse pregnancy outcomes
• a pediatric pharmacokinetic and pharmacodynamic study
Those same trials, meanwhile, have clearly demonstrated that SGLT2 inhibitors produce unique benefits and may thus prove to be considerably more useful than many originally expected.


REFERENCES
 
1. Clarke T. US FDA approves Johnson & Johnson diabetes drug, canagliflozin. Reuters website. http://www.reuters.com/article/2013/03/29/johnsonjohnson-diabetes-idUSL3N-0CL1FV20130329. Published March 29, 2013. Accessed February 17, 2015.
 
2. Market brief: The market for type 2 diabetes therapeutics; key findings from a recent analysis of global drug development efforts. Drug Development and Delivery website. http://drug-dev.com/Main/Back-Issues/MARKET-BRIEF-The-Market-for-Type-2-Diabetes-Therap-641.aspx. Published November 19, 2013. Accessed February 17, 2015.
 
3. Simon JL, Timaeus S, Misita C. SGLT2 inhibitors: a new treatment option for type 2 diabetes. Pharmacy Times. http://www.pharmacytimes.com/publications/health-system-edition/2014/September2014/SGLT2-Inhibitors-A-New-Treatment-Option-for-Type-2-Diabetes. Published September 17, 2014. Accessed February 17, 2015.
 
4. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension [published online September 30, 2014]. Diabetes Care. doi:10.2337/dc14-1096.
 
5. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8(5):330-339.
 
6. Klein R, Klein BEK, Lee KE, Cruickshanks KJ, Moss SE. The incidence of hypertension in insulin-dependent diabetes. Arch Intern Med. 1996;156(6):622-627.
 
7. Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-885.
 
8. Jabbour SA. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem. Postgrad Med. 2014; 126(1):111-117.
 
9. Kohan DE, Fiorett P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney International 2014; 85:962-971.
 
10. Maliha G, Townsend RR. SLGT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens. 2015; 9(1):48-53.
 
11. Hughes AD. How do thiazide and thiazide-like diuretics lower blood pressure? J Renin Angiotensin Aldosterone Syst. 2004;5(4):155-160. 12. Williams S. 5 things Johnson & Johnson’s management wants you to know. Motley Fool website. http://www.fool.com/investing/general/2015/01/26/5-things-johnson-johnsons-management-wants-you-to.aspx. Published January 26, 2015. Accessed February 17, 2015.
 
13. El-Shafie K, Rizvi S. Control of hypertension among type 2 diabetes. Oman Med J. 2010; 25(1):32-36.
 
14. Harris MI, Eastman RC, Cowie CC, et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 1999;22(3):403-408.
 
15. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea. Diabetes Care. 2013;36(9):2508-2515.
 
16. Merck announces 4th quarter and full year 2013 results [press release]. Whitehouse Station, NJ: Business Wire; February 5, 2014. http://www.businesswire.com/news/home/20140205005626/en/Merck-Announces-Fourth-Quarter-Full-Year-2013-Financial-Results#.VOO5J_nF-Sp.
 
17. Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37(3):740-750.
 
18. Invokana website. Invokana monotherapy provided statistically significant reductions in A1C vs placebo at 26 weeks. http://www.invokanahcp.com/clinical-research-results/monotherapy-vs-placebo/A1C-reductions. Accessed February 17, 2015.
 
p 19. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208-219.
 
20. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217-2224.
 
21. Bailey CJ, Day C. SGLT2 inhibitors: glucuretic treatment for type 2 diabetes. Medscape website. http://www.medscape.com/viewarticle/726748_1. Accessed February 18, 2015.
 
22. Edney A. Bristol-AstraZeneca drug wins US FDA approval. Bloomberg News website. http://www.bloomberg.com/news/articles/2014-01-08/bristol-astrazeneca-diabetes-drug-wins-u-s-fda-approval. Published January 8, 2014. Accessed February 17, 2015.
 
23. Tucker ME. Most FDA advisers support diabetes drug canagliflozin, despite CV concerns. Medscape website. http://www.medscape.com/viewarticle/791413. Published January 11, 2013. Accessed February 17, 2015.
 
24. FDA approves Invokana to treat type 2 diabetes [press release]. Silver Spring, MD: FDA Newsroom; March 23, 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm.
PDF
<< Previous Page (1)Page: 12
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up